Blurbs

JMP Securities Reaffirms Their Buy Rating on Hookipa Pharma (HOOK)

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Hookipa Pharma (HOOKResearch Report) today and set a price target of $8.00. The company’s shares opened today at $1.19.

Buchanan covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma, Dynavax, and PolyPid. According to TipRanks, Buchanan has an average return of -28.9% and a 25.26% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hookipa Pharma with a $8.75 average price target.

See today’s best-performing stocks on TipRanks >>

HOOK market cap is currently $68.38M and has a P/E ratio of -0.65.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body’s immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Read More on HOOK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More